Separase Inhibition Enhances Gefitinib Sensitivity of Lung Cancer via PTBP1/TAK1/RIPK1‐Mediated PANoptosis
ABSTRACT Gefitinib is the most frequently employed anti‐lung cancer drug, but its clinical effectiveness is often compromised due to the development of drug resistance. Given that gefitinib failure to long‐term inhibition of the growth of lung carcinoma cell lines, which mirrors the resistance obser...
Furkejuvvon:
| Váldodahkkit: | , , , |
|---|---|
| Materiálatiipa: | Artigo |
| Giella: | Inglês |
| Almmustuhtton: |
Wiley
2025-11-01
|
| Ráidu: | MedComm |
| Fáttát: | |
| Liŋkkat: | https://doi.org/10.1002/mco2.70432 |
| Fáddágilkorat: |
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|